Iovance Biotherapeutics, Inc. - Common Stock (IOVA)

Iovance Biotherapeutics is a clinical-stage biotechnology company focused on the development and commercialization of novel cell therapy products for the treatment of cancer

The company specializes in the use of tumor-infiltrating lymphocyte (TIL) therapy, which harnesses the body’s immune system to target and destroy cancer cells. By processing and expanding patients' own immune cells, Iovance aims to create personalized therapies that can provide effective options for those with various types of solid tumors. Their innovative approach leverages advancements in cell therapy to improve patient outcomes and contribute to the evolving landscape of cancer treatment.